Low-dose abiraterone (abi) with food in men with metastatic castration-resistant prostate cancer (mCRPC): The Princess Margaret Cancer Centre experience.

被引：0
|
作者：
Leibowitz-Amit, Raya
Atenafu, Eshetu G.
Seah, Jo-An
Templeton, Arnoud J.
Vera-Badillo, Francisco Emilio
Alimohamed, Nimira S.
Knox, Jennifer J.
Sridhar, Srikala S.
Tannock, Ian
Joshua, Anthony M.
机构：
[1] Univ Toronto, Div Med Oncol, Princess Margaret Hosp, Toronto, ON, Canada
[2] Princess Margaret Canc Ctr, Dept Biostat, Toronto, ON, Canada
[3] Univ Toronto, Princess Margaret Canc Ctr, Univ Hlth Network, Dept Med, Toronto, ON, Canada
[4] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada
[5] Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada
[6] Univ Toronto, Dept Med Oncol, Princess Margaret Canc Ctr, Univ Hlth Network, Toronto, ON, Canada
[7] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
[8] Princess Margaret Hosp, Univ Hlth Network, Toronto, ON M4X 1K9, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.5077
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5077
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Dose-modified abiraterone acetate (AA) in men with metastatic castration-resistant prostate cancer (mCRPC): The Princess Margaret Cancer Centre (PM) experience
    Leibowitz-Amit, Raya
    Atenafu, Eshetu G.
    Seah, Jo-An
    Templeton, Arnoud J.
    Vera-Badillo, Francisco Emilio
    Solow, Henry L.
    Knox, Jennifer J.
    Sridhar, Srikala S.
    Tannock, Ian
    Joshua, Anthony Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [2] Clinical activity of enzalutamide against metastatic castration-resistant prostate cancer (mCRPC) in patients who have progressed on abiraterone acetate: The Princess Margaret experience.
    Vera-Badillo, Francisco Emilio
    Leibowitz-Amit, Raya
    Templeton, Arnoud
    Seah, Jo-An
    Sridhar, Srikala S.
    Knox, Jennifer J.
    Tannock, Ian
    Joshua, Anthony Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [3] Low-dose abiraterone with fatty food versus standard dose abiraterone in metastatic castration-resistant prostate cancer
    Shaherose, S.
    Charu, G. Katta
    Santa, A.
    Rajappa, S. J.
    Mohan, K.
    Boyella, P. K.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S1496 - S1496
  • [4] Abiraterone acetate in metastatic castration-resistant prostate cancer: A retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole
    Leibowitz-Amit, Raya
    Seah, Jo-An
    Atenafu, Eshetu G.
    Templeton, Arnoud J.
    Vera-Badillo, Francisco E.
    Alimohamed, Nimira
    Knox, Jennifer J.
    Tannock, Ian F.
    Sridhar, Srikala S.
    Joshua, Anthony M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 (14) : 2399 - 2407
  • [5] Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC).
    Maughan, Benjamin Louis
    Suzman, Daniel L.
    Nadal, Rosa
    Bassi, Sunakshi
    Schweizer, Michael Thomas
    Antonarakis, Emmanuel S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [6] The survival outcomes for men with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination deficiencies (HRD) treated with radium-223: Princess Margaret Cancer Centre (PMCC) experience.
    Al-Ezzi, Esmail M.
    Abdeljalil, Osama
    Lajkosz, Katherine
    Gramolini, Shreya S.
    Mejia, Nely Mercy Diaz
    Alqaisi, Husam
    Peng, Jenny
    O'Dwyer, Richard Thomas
    Alghamdi, Mohammed
    Almuthri, Sulaiman
    Kumar, Vikaash
    Jiang, Di Maria
    Fallah-Rad, Nazanin
    Sridhar, Srikala S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 179 - 179
  • [7] Optimal sequencing of enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC)
    Maughan, Benjamin Louis
    Suzman, Daniel L.
    Nadal, Rosa Maria
    Bassi, Sunakshi
    Antonarakis, Emmanuel S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [8] The study of the treatment efficacy in metastatic castration-resistant prostate cancer of low dose abiraterone with food.
    Makphanchareonkit, Kanta
    Dejthevaporn, Thitiya Sirisinha
    Muntham, Dittapol
    Chansriwong, Phichai
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] ABIraterone (ABI) and ENZalutamide (ENZ) induce changes in immunologic profile of patients with metastatic castration-resistant prostate cancer (mCRPC)
    Salgia, Meghan
    Perez, Marc L.
    Jones, Jeremy
    Won, Hae Jung
    Poroyko, Valeriy
    Twardowski, Przemyslaw
    Kortylewski, Marcin
    Pal, Sumanta K.
    [J]. CANCER RESEARCH, 2017, 77
  • [10] From trial to practice: The Princess Margaret Hospital (PMH) experience with docetaxel and prednisone for men with metastatic castration resistant prostate cancer (mCRPC)
    Templeton, Arnoud
    Wang, Lisa
    Vera-Badillo, Francisco
    Attalla, Mirna
    De Gouveia, Paulo
    Leibowitz-Amit, Raya
    Knox, Jennifer J.
    Moore, Malcolm J.
    Sridhar, Srikala S.
    Joshua, Anthony Michael
    Tannock, Ian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
12345